FDA Releases Draft Guidance for OTC Labeling - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Releases Draft Guidance for OTC Labeling

ePT--the Electronic Newsletter of Pharmaceutical Technology

Rockville, MD (Dec. 8)—The US Food and Drug Administration released a draft guidance document that contains questions and answers relating to new labeling requirements for over-the-counter drug (OTC) products that are marketed without an approved application under section 502(x) of the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006.

Specifically, the guidance document discusses the following:

  • The meaning of “domestic address” as referenced in section 502(x)
  • The agency’s recommendation for the use of an introductory statement before the domestic address or phone number that is required to appear on the product label according to section 502(x)
  • The agency’s intent regarding enforcement of the labeling requirements under section 502(x).

FDA intends to begin enforcement of section 502(x) “on or after Jan. 1, 2010,” or more than two years after this section of the Act became effective, which was on December 22, 2007.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here